These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Use of a noninvasive continuous monitoring device in the management of atrial fibrillation: a pilot study.
    Author: Rosenberg MA, Samuel M, Thosani A, Zimetbaum PJ.
    Journal: Pacing Clin Electrophysiol; 2013 Mar; 36(3):328-33. PubMed ID: 23240827.
    Abstract:
    BACKGROUND: Outpatient ambulatory cardiac rhythm monitoring is a routine part of the management of patients with paroxysmal atrial fibrillation (AF). Current systems are limited by patient convenience and practicality. METHODS: We compared the Zio(®) Patch, a single-use, noninvasive waterproof long-term continuous monitoring patch, with a 24-hour Holter monitor in 74 consecutive patients with paroxysmal AF referred for Holter monitoring for detection of arrhythmias. RESULTS: The Zio(®) Patch was well tolerated, with a mean monitoring period of 10.8 ± 2.8 days (range 4-14 days). Over a 24-hour period, there was excellent agreement between the Zio(®) Patch and Holter for identifying AF events and estimating AF burden. Although there was no difference in AF burden estimated by the Zio(®) Patch and the Holter monitor, AF events were identified in 18 additional individuals, and the documented pattern of AF (persistent or paroxysmal) changed in 21 patients after Zio(®) Patch monitoring. Other clinically relevant cardiac events recorded on the Zio(®) Patch after the first 24 hours of monitoring, including symptomatic ventricular pauses, prompted referrals for pacemaker placement or changes in medications. As a result of the findings from the Zio(®) Patch, 28.4% of patients had a change in their clinical management. CONCLUSIONS: The Zio(®) Patch was well tolerated, and allowed significantly longer continuous monitoring than a Holter, resulting in an improvement in clinical accuracy, the detection of potentially malignant arrhythmias, and a meaningful change in clinical management. Further studies are necessary to examine the long-term impact of the use of the Zio(®) Patch in AF management.
    [Abstract] [Full Text] [Related] [New Search]